Fundz

Lys Therapeutics Raises Over €25 Million in Funding to Advance LYS241 for Clinical Development. The financing includes a grant exceeding $5 million from The Michael J. Fox Foundation.

PRIVATEJun 22, 2026

Amount Raised

€25 Million

Round Type

Grant

BiotechnologyHealth CareTherapeutics

Investors

France 2030BpifranceThe Michael J. Fox Foundation

Description

Lys Therapeutics, a biotechnology company from France, has raised over €25 million since its founding in 2021. The financing includes a significant grant to advance LYS241, a novel neurovascular antibody. The proceeds will support clinical entry and regulatory studies. Recent preclinical data highlight LYS241's potential to address key neurological challenges.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Lys Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Tarsus Pharmaceuticals raised $125M (Post-IPO Equity) on August 6, 2026.
  • Expedition raised $115M (Series B) on August 5, 2026.
  • Acasti raised $10M on August 4, 2026.
  • GentiBio raised $1.2M (Grant) on August 2, 2026.
  • Ratio Therapeutics raised $70M (Series C) on July 31, 2026.
  • Hyku Biosciences raised $8.6M on July 30, 2026.

Who to call at Lys Therapeutics, and when

A new round usually means Lys Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Lys Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Lys Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Lys Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Lys Therapeutics

About

Lys Therapeutics is a French biotechnology company pioneering a novel approach targeting the tPA-NMDAr axis in neurodegenerative and neurovascular diseases. The company focuses on developing innovative monoclonal antibodies to address mechanisms associated with blood-brain barrier dysfunction and related conditions. Their lead candidate, LYS241, is designed to selectively block pathological interactions while preserving physiological functions. The company aims to translate neurovascular biology into disease-modifying therapies for severe neurological disorders.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Lys Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Lys Therapeutics's next move

See what Strategic adds

Lys Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.